Raxibacumab: Difference between revisions
(Creation of page) |
ClaireLewis (talk | contribs) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 35: | Line 35: | ||
==Special Populations== | ==Special Populations== | ||
===[[Drug pregnancy categories|Pregnancy Rating]]=== | ===[[Drug pregnancy categories|Pregnancy Rating]]=== | ||
* | *Category B: benefits outweigh risks during pregnancy | ||
===Lactation risk=== | ===Lactation risk=== | ||
| Line 77: | Line 77: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:ID]] | |||
Latest revision as of 22:16, 23 September 2019
Administration
- Type: Monoclonal antibody
- Dosage Forms: INJ
- Routes of Administration: IV
- Common Trade Names: N/A
Adult Dosing
Distributed directly to CDC
Inhalational anthrax treatment
- 40 mg/kg IV x1
- Premedicate with antihistamine
Inhalational anthrax prophylaxis, post-exposure
- 40 mg/kg IV x1
- Premedicate with antihistamine
Pediatric Dosing
Inhalational anthrax treatment
- <10 kg
- 80 mg/kg IV x1
- 10-40 kg
- 60 mg/kg IV x1
- >40 kg
- 40 mg/kg IV x1
- Premedicate with antihistamine
Inhalational anthrax prophylaxis, post-exposure
- <10 kg
- 80 mg/kg IV x1
- 10-40 kg
- 60 mg/kg IV x1
- >40 kg
- 40 mg/kg IV x1
- Premedicate with antihistamine
Special Populations
Pregnancy Rating
- Category B: benefits outweigh risks during pregnancy
Lactation risk
- Benefits outweigh risks while breast feeding
Renal Dosing
- Adult: Not defined
- Pediatric: Not defined
Hepatic Dosing
- Adult: Not defined
- Pediatric: Not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Infusion reaction
Common
- Rash, pruritus
- Extremity pain
Pharmacology
- Half-life: 22 days
- Metabolism: Unknown
- Excretion: Unknown
Mechanism of Action
- Binds to anthrax toxin